Business Description
CASI Pharmaceuticals Inc
ISIN : US14757U1097
Total Employee Number:
214Description
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | -1.45 | |||||
Debt-to-Equity | -0.74 | |||||
Debt-to-EBITDA | -0.61 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -47.48 | |||||
Beneish M-Score | -11.99 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -29.3 | |||||
3-Year EBITDA Growth Rate | 2.7 | |||||
3-Year EPS without NRI Growth Rate | -5.4 | |||||
3-Year FCF Growth Rate | 16.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.27 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.36 | |||||
9-Day RSI | 47.55 | |||||
14-Day RSI | 48.45 | |||||
3-1 Month Momentum % | -5.89 | |||||
6-1 Month Momentum % | -86.01 | |||||
12-1 Month Momentum % | -91.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.27 | |||||
Quick Ratio | 0.24 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 116.75 | |||||
Days Sales Outstanding | 123.39 | |||||
Days Payable | 43.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 | |||||
Shareholder Yield % | -199.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 48.65 | |||||
Operating Margin % | -206.84 | |||||
Net Margin % | -232 | |||||
EBITDA Margin % | -217.42 | |||||
FCF Margin % | -100.34 | |||||
OCF Margin % | -100.2 | |||||
ROA % | -136.66 | |||||
ROIC % | -124.3 | |||||
3-Year ROIIC % | -173.2 | |||||
ROC (Joel Greenblatt) % | -382.71 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.11 | |||||
EV-to-EBIT | -0.54 | |||||
EV-to-EBITDA | -0.54 | |||||
EV-to-Revenue | 1.18 | |||||
EV-to-Forward-Revenue | 3.82 | |||||
EV-to-FCF | -1.18 | |||||
Price-to-GF-Value | 0.12 | |||||
Earnings Yield (Greenblatt) % | -185.19 | |||||
FCF Yield % | -777.81 |
CASI Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CASI Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 62 days | ||
| First quarter earnings results for 2026 | 2026-07-01 | In 4 days | ||
| General meeting for 2025 | 2026-07-01 | In 4 days | ||
| Annual report for 2025 | 2026-05-15 | 0.14 (-17.65%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.34 (-5.99%) | ||
| Guggenheim Healthcare Innovation Conference | 2025-11-12 09:30 | 1.38 (+2.99%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 10:00 | 2.34 (+5.41%) | ||
| Guidance call for 2025 | 2025-09-03 11:30 | 2.30 (+3.60%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 2.44 (+11.42%) |
Show
Entries
Guru Commentaries on OTCPK:CASIF
No articles.
Press Release
Articles on CASI Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers